相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
ADVANCES IN THERAPY (2009)
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Abd A. Tahrani et al.
ADVANCES IN THERAPY (2009)
Comment on: Torii et al. (2009) Gene Silencing of Phogrin Unveils Its Essential Role in Glucose-Responsive Pancreatic -Cell Growth. Diabetes 58:682-692
Y. Hu et al.
DIABETES (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections
Aberra Fura et al.
DRUG METABOLISM AND DISPOSITION (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Effect of Sitagliptin on the Pharmacokinetics of Simvastatin
Arthur J. Bergman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction
Robert V. DiGregorio et al.
PHARMACOTHERAPY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Prevalence, treatment, and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004
Kwok Leung Ong et al.
ANNALS OF EPIDEMIOLOGY (2008)
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
Goutam C. Mistry et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Javaid H. Wani et al.
CARDIOLOGY CLINICS (2008)
Emergency contraception: A reasonable personal choice or a destructive societal influence?
M. F. Greene
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Postmenopausal hormone therapy for disease prevention: Have we learned any lessons from the past?
J. E. Rossouw
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
Ronald Christopher et al.
CLINICAL THERAPEUTICS (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Looking to the future - Focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies
Joshua J. Neumiller et al.
DIABETES EDUCATOR (2008)
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
C. Pan et al.
DIABETIC MEDICINE (2008)
Vildagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Jamie D. Croxtall et al.
DRUGS (2008)
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
Bumsup Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Janumet™: a combination product suitable for use in patients with Type 2 diabetes
Jonathan Kent Reynolds et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Paget's disease of the mandible
Mayank B. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia
Rory J. McCrimmon et al.
DIABETES (2008)
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
Surya P. Ayalasomayajula et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes
A. Schweizer et al.
DIABETIC MEDICINE (2007)
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers
Yon-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
Y.-L. He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
The role of vildagliptin in the management of type 2 diabetes mellitus
Erika L. Kleppinger et al.
ANNALS OF PHARMACOTHERAPY (2007)
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
F. Xavier Pi-Sunyer et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
S. Dejager et al.
HORMONE AND METABOLIC RESEARCH (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects
Rajesh Krishna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
The physiology of incretin hormones and the basis for DPP-4 Inhibitors
Skye Aiko McKennon et al.
DIABETES EDUCATOR (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system
Antonios E. Panteleon et al.
DIABETES (2006)
Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Shannon A. Miller et al.
ANNALS OF PHARMACOTHERAPY (2006)
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
R. E. Pratley et al.
HORMONE AND METABOLIC RESEARCH (2006)
Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002 - The National Health and Nutrition Examination Survey
HE Resnick et al.
DIABETES CARE (2006)
Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin.
D Wright et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)
YB Kim et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
I Brandt et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo
P He et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes
AE Weber
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Glucagon-like peptide-1:: a major regulator of pancreatic β-cell function
R Perfetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000)
分享论文
